No Collateral Estoppel Against Unnamed Putative Class Members, Where Certification Is Denied

by charlesjung

English: Access denied

Image via Wikipedia

The Court of Appeal for the Second District held that a denial of class certification cannot establish collateral estoppel against unnamed putative class members. Bridgeford v. Pacific Health Corporation, et al., No. B227486, 202 Cal.App.4th 1034 (2d Dist. Jan. 18, 2012).

Background

Plaintiffs Bridgeford and Tarin filed a class action complaint in May 2010 against Pacific Health Corporation and other entities, alleging that defendants committed numerous wage and hour violations, including (1) failure to pay wages due upon discharge or resignation, (2) failure to pay regular and overtime wages due semimonthly, (3) failure to provide meal breaks, (4) failure to provide rest breaks, (5) failure to provide itemized wage statements, (6) failure to pay minimum wages for time worked off-the-clock, (7) failure to pay overtime wages, and (8) unfair competition.  Id.

The trial court sustained a demurrer without leave to amend.  Id.  Plaintiff’s appealed, contending the trial court misapplied the doctrine of collateral estoppel in holding that their class claims are precluded, and there is no basis to dismiss their individual claims or their representative claims under the Labor Code Private Attorneys General Act of 2004 (PAGA) (Lab. Code section 2698, et seq.).

Discussion

Following the recent U.S. Supreme Court decision in Smith v. Bayer  Corporation, — U.S. —-, 131 S.Ct. 2368, 180 L.Ed.2d 341 (2011), the Second District held that unnamed putative members of a class that was never certified cannot be bound by collateral estoppel.   Id. The court concluded that “if no class was certified by the court in the prior proceeding, the interests of absent putative class members were not represented in the prior proceeding and the requirements for collateral estoppel cannot be established . . . .”  Id.

The Second District discussed the Bayer case:

Applying common law principles of issue preclusion, the high court held that unnamed putative class members cannot be bound by issue preclusion if the class was never certified in the prior proceeding.   (Id. at pp. 2380-2381.)   Smith v. Bayer  Corporation stated, “[n]either a proposed class action nor a rejected class action may bind nonparties” (id. at p. 2380), and, “[t]he great weight of scholarly authority … agrees that an uncertified class action cannot bind proposed class members.”   (Id. at p. 2381, fn. 11.)   The high court explained that unnamed putative class members as nonparties can be bound by issue preclusion only if there was a properly certified class because only in those circumstances can the court in the later proceeding conclude that their interests were adequately represented in the prior proceeding.   (Id. at pp. 2379-2381 & fn. 11.)

The Second District found the reasoning persuasive and concluded that “under California law, that the denial of class certification cannot establish collateral estoppel against unnamed putative class members on any issue because unnamed putative class members were neither parties to the prior proceeding nor represented by a party to the prior proceeding so as to be considered in privity with such a party for purposes of collateral estoppel.”  Id.

The court reasoned that since plaintiffs were not named plaintiffs in a prior case and the trial court in the prior case denied class certification, “plaintiffs as unnamed putative class members . . . cannot be bound by collateral estoppel with respect to any issue decided in connection with the denial of class certification.” Id.

Judges and Attorneys

Associate Justice H. Walter Croskey wrote the opinion for the Court.  Presiding Justice Joan D. Klein and Associate Justice Patti S. Kitching concurred.

Law Offices of Mark Yablonovich, Mark Yablonovich, Los Angeles, Neda Roshanian and Michael D. Coats for Plaintiffs and Appellants.

Silver & Freedman, Los Angeles, Andrew B. Kaplan and Jeffrey W. Mayes for Defendants and Respondents.

By CHARLES JUNG

Enhanced by Zemanta
Advertisement